Neurosciences articles for United Kingdom (UK)

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 214

Article ‘Count’ for Neurosciences.

Journal Count Share
1 0.08
Sonodynamic and Bioorthogonal Sonocatalytic Thrombotic Therapy Based on AIE Cationic Tetranuclear Ir(III) Complex Nanoplatform Guided by NIR‐Chemiluminescence Imaging 0.08
1 0.06
Landscapes of missense variant impact for human superoxide dismutase 1 0.06
1 0.16
The effects of lacosamide, pregabalin, and tapentadol on peripheral nerve excitability: A randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects. 0.16
16 5.57
Effects of Blood Pressure Lowering Across Hematoma Volume in Acute Intracerebral Hemorrhage: Pooled Analysis of the Four INTERACT and ATACH-2 Trials 0.04
Predominance of Ferroptotic Cell Death Mechanisms in Substantia Nigra Neurodegeneration in Parkinson's Disease 0.08
The Clinical Spectrum and Neurodevelopmental Pathogenesis of KPTN-Related Disorder in a Mouse Model 0.35
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling 0.13
Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale 0.31
Mutations in the Key Autophagy Tethering Factor scpEPG5/scp Link Neurodevelopmental and Neurodegenerative Disorders Including Early‐Onset Parkinsonism 0.16
Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic Study 0.12
Microneurography Reveals Unmyelinated Small Nerve Fiber Dysfunction in Long scpCOVID/scp 1.00
Clinical–Radiological Spectrum of Cerebral Amyloid Angiopathy‐Related Inflammation 0.90
Clinical and Molecular Genetic Characterization of Landau Kleffner Syndrome: An Observational Cohort and Experimental Study 0.66
iHCN2/i‐Associated Neurodevelopmental Disorders: Data from Patients and iXenopus/i Cell Models 0.04
Disease Progression in Multiple System Atrophy: The scpASPIRE/scp Multi‐Modal Biomarker Study 0.04
Persisting Transglutaminase 6 Antibodies in Neurological Gluten‐Related Disorders 1.00
Brain Endothelial Soluble scpST2/scp Production and Cerebral Edema in a Rat Model of Ischemic Stroke 0.06
Heart Rate Profiles During Exercise and Incident Parkinson's Disease 0.49
Deep Brain Stimulation for scpiVPS16/i/scp‐Related Dystonia: A Multicenter Study 0.19
2 0.29
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study 0.17
Visual hypersensitivity as a transdiagnostic marker of surgical pain response in arthritis and chronic pain syndromes 0.13
36 18.36
Nav1.5 in the dorsal root ganglion plays a crucial role in mechanical hypersensitivity 0.27
Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression 0.04
Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD+ 0.14
Spatial propagation of movement-related basal ganglia activity predicts parkinsonian motor state 0.11
Enhanced mGluR1 function causes motor deficits and region-specific Purkinje cell dysfunction 0.95
A cause and protective treatment for acute and progressive disability and grey matter atrophy 0.87
Immune alterations in schizophrenia and the effects of a therapeutic antibody: a neuroimaging study 0.87
Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer's disease 1.00
PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models 0.25
A next-generation HDAC6 inhibitor for amyotrophic lateral sclerosis and frontotemporal dementia 0.06
Enhanced adenoviral reactivity in Guillain-Barré syndrome after SARS-CoV-2 infection and vaccination 0.85
The presymptomatic and early manifestations of semantic dementia 1.00
Targeting lipid droplets in FUS-linked amyotrophic lateral sclerosis mitigates neuronal and astrocytic lipotoxicity 0.20
Cortical tau deposition promotes atrophy in connected white matter regions in Alzheimer’s disease 0.08
Genotype-specific interferon signatures in amyotrophic lateral sclerosis relate to disease severity 0.31
Quantitative susceptibility mapping reveals differences between subtypes of Lewy body dementia 1.00
Brain signatures of nociplastic pain: Fibromyalgia Index and descending modulation at population level 0.91
Molecular and clinical spectrum of epilepsy-dyskinesia syndromes: a cross-sectional study of 609 patients 0.09
Associations between epilepsy-related polygenic risk and brain morphology in childhood 0.07
Traumatic brain injury or head impacts from contact sports are associated with tau astrogliopathy 0.10
Behavioural changes in frontotemporal dementia and their cognitive and neuroanatomical correlates 1.00
Transcriptomic disruption and hypoactivity in DYT-SGCE medial ganglionic eminence-patterned inhibitory neurons 1.00
Neurodegenerative disease in iC9orf72/i repeat expansion carriers: population risk and effect of iUNC13A/i 1.00
Brain atrophy patterns in anti-IgLON5 disease 0.01
The influence of the glymphatic system on α-synuclein propagation: the role of aquaporin-4 1.00
Extreme exercise in males is linked to mTOR signalling and onset of amyotrophic lateral sclerosis 0.63
Cholinergic patterns correlate with dopamine medication ON freezing of gait in Parkinson’s disease 0.09
Amygdalar and hippocampal volume loss in limbic-predominant age-related TDP-43 encephalopathy 0.03
A digital motor score for sensitive detection of progression in Huntington’s disease 0.27
Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of iPMP22/i variants 0.08
Redefining diagnostic lesional status in temporal lobe epilepsy with artificial intelligence 0.06
Raised intracranial pressure alters cortical vascular function and cephalic allodynia 1.00
Post-mortem validation of in vivo TSPO PET as a microglial biomarker 0.93
Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan 0.21
Pure autonomic failure: a natural history study of the Queen Square cohort 0.95
Cholinergic degeneration in prodromal and early Parkinson’s: a link to present and future disease states 0.95
1 0.97
The NEON (Nerve rEpair Or Not) trial: a randomized controlled trial of microsurgical repair iversus/i nerve alignment for digital nerve injury 0.97
2 0.83
A glycolytic shunt via the pentose phosphate pathway is a metabolic checkpoint for nervous system sensory homeostasis and axonal regeneration 0.63
The effect of shingles vaccination at different stages of the dementia disease course 0.20
1 0.96
Detecting alpha-synuclein aggregates with small molecules on single-molecule array 0.96
1 0.09
Electroencephalogram Features Distinguish Cases of Cerebral Malaria Among Malawian Children With Fever and Coma 0.09
1 0.03
Remote ischaemic conditioning improves outcomes of ischaemic stroke treated by endovascular thrombectomy: the SERIC-EVT trial 0.03
1 0.08
Sensory neurons shape local macrophage identity via TGF-β signaling 0.08
1 0.04
Risk of stroke, myocardial infarction, coronary intervention, and atrial fibrillation or flutter in individuals experiencing typical migraine aura without headache: a Danish registry-based cohort study 0.04
1 0.08
Long-term fasting-induced parasympathetic and sympathetic autonomic nervous system modulation in a subgroup of the GENESIS study 0.08
2 1.45
Intracranial Pressure Treatment Thresholds in Pediatric Traumatic Brain Injury 0.95
Prenatal Exposure to Zika Virus and Risk of Epilepsy-Related Hospitalization During Early Childhood 0.50
1 0.16
Multivariate Brain-Blood Signatures in Early-Stage Depression and Psychosis 0.16
4 0.13
Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke 0.02
Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke 0.02
Levodopa Added to Stroke Rehabilitation 0.02
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity 0.07
1 0.80
Seeding biosensor cell line that reproduces the Alzheimer tau fold 0.80
1 0.71
Lysosomal TPC2 channels disrupt Ca2+ entry and dopaminergic function in models of LRRK2-Parkinson’s disease 0.71
3 0.56
Pathogenic variants in BORCS5 Cause a Spectrum of Neurodevelopmental and Neurodegenerative Disorders with Lysosomal Dysfunction 0.19
Biallelic variants in ARHGAP19 cause a progressive inherited motor-predominant neuropathy 0.36
Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models 0.01
4 1.37
Bed nucleus of stria terminalis enkephalin neurons contribute to depletion-induced salt appetite 0.05
Toward Unified Biomarkers for Focal Epilepsy 0.08
Peripheral Gating of Nociception Investigated with a Decerebrate, Arterially Perfused Preparation of the Rat 0.54
Projection of Cortical Beta Band Oscillations to a Motor Neuron Pool Across the Full Range of Recruitment 0.70
7 4.02
Psychological stress catalyses free radical–mediated activation of coagulation in humans 0.97
Photobiomodulation restores blood–brain barrier integrity after hypoxia via endothelial von Willebrand factor modulation in a humanised tricellular transwell model 0.60
Trafficking and potentiation of Nav1.7 and Nav1.8 channels are mediated by IQGAP1 1.00
Ageing does not impair motor neuron adaptations: comparable motor unit responses to strength training in young and older adults 0.17
Ventilatory and cerebrovascular responses to exercise in lowlander children acclimatizing to high‐altitude 0.14
Non‐invasive assessment of integrated cardiorespiratory network dynamics after physiological stress in humans 1.00
Neural determinants of the increase in muscle strength and force steadiness of the untrained limb following a 4 week unilateral training 0.14
3 2.11
Mapping the Role of Monomer Conformation in the Amyloid Formation of α-Synuclein Splice Variants 1.00
Design of Tau Aggregation Inhibitors Using Iterative Machine Learning and a Polymorph-Specific Brain-Seeded Fibril Amplification Assay 0.49
Spectroscopic Characterization of Radical Pair Photochemistry in Nonmigratory Avian Cryptochromes: Magnetic Field Effects in GgCry4a 0.63
5 1.96
Positive bias in brain and behaviour as a mechanism of transcranial magnetic stimulation depression treatment 0.30
Alzheimer’s disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography 1.00
Cortical microstructure is associated with disease severity and clinical progression in genetic frontotemporal dementia: a GENFI study 0.16
Gesture deficits in psychosis and the combination of group psychotherapy and transcranial magnetic stimulation: A randomized clinical trial 0.06
Thalamo-frontal functional connectivity patterns in Tourette Syndrome: Insights from combined intracranial DBS and EEG recordings 0.44
5 2.85
Population-scale repeat expansions elucidate disease risk and brain atrophy 0.01
Intestinal macrophages modulate synucleinopathy along the gut–brain axis 0.70
Quantum spin resonance in engineered proteins for multimodal sensing 0.69
A probabilistic histological atlas of the human brain for MRI segmentation 0.69
SLC45A4 is a pain gene encoding a neuronal polyamine transporter 0.77
1 0.14
Small-molecule dissolution of stress granules by redox modulation benefits ALS models 0.14
35 11.43
Dysfunction of the episodic memory network in the Alzheimer’s disease cascade 0.02
Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality 0.26
Suppression of pathological oscillations with transcranial focused ultrasound in Parkinson’s disease 0.97
Selective weakening of population-coupled synaptic activity in vivo in a mouse model of amyloid-beta pathology 1.00
NF-κB activation in astrocytes impairs wound healing after traumatic brain injury in male mice 0.05
An in vivo and in vitro spatiotemporal profile of human midbrain development 0.88
Spinal cord stimulation therapy for gait impairment in Parkinson’s disease: a double-blinded, randomised feasibility trial with an open extension 0.16
Identification of a thermogenic target in the dorsal raphe nucleus for weight management in mice 0.13
No causal links between estradiol and female’s brain and mental health using Mendelian randomization 0.19
Aberrant neural activity in the peritumoral cortex underlies the progression of tumor-associated seizures 0.08
Evidence for divergent cortical organisation in Parkinson’s disease and Lewy Body Dementia 1.00
Prefrontal–bed nucleus of the stria terminalis physiological and neuropsychological biomarkers predict therapeutic outcomes in depression 0.21
Molecular profiling of brain endothelial cell to astrocyte endfoot communication in mouse and human 1.00
Distinct spatiotemporal patterns of white matter hyperintensity progression 0.06
Seed structure and phosphorylation in the fuzzy coat impact tau seeding competency 0.18
Astrocytes modulate neuronal development by S100A6 signaling 0.05
Estrogen-related receptor gene expression associates with sex differences in cortical atrophy in isolated REM sleep behavior disorder 0.06
A wireless optogenetic stimulation system for long-term function evaluation of mice forelimb with sub-nerve resolution 0.08
Isotope-encoded spatial biology identifies plaque-age-dependent maturation and synaptic loss in an Alzheimer’s disease mouse model 0.33
CSF total tau as a proxy of synaptic degeneration 0.01
Prefrontal cortex astrocytes modulate distinct neuronal populations to control anxiety-like behavior 0.13
Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification 0.03
The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis 0.32
Accelerated brain ageing during the COVID-19 pandemic 1.00
A human brain network linked to restoration of consciousness after deep brain stimulation 0.02
AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial 0.71
Mechanically robust neuroprotective stent by sequential Mg ions release for ischemic stroke therapy 0.07
Synaptic loss pattern is constrained by brain connectome and modulated by phosphorylated tau in Alzheimer’s disease 0.02
Chronic cerebral hypoperfusion induces venous dysfunction via EPAS1 regulation in mice 0.05
Cell-specific mechanisms drive connectivity across the time course of Huntington’s disease 0.58
Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer’s disease 0.02
Intracellular accumulation of amyloid-ß is a marker of selective neuronal vulnerability in Alzheimer’s disease 1.00
Atlas of Proteomic signatures of brain structure and its links to brain disorders 0.05
Single-cell RNA-sequencing reveals early mitochondrial dysfunction unique to motor neurons shared across FUS- and TARDBP-ALS 0.36
Machine learning-based meta-analysis reveals gut microbiome alterations associated with Parkinson’s disease 0.36
3 0.40
Somatic mosaicism in ALS and FTD identifies focal mutations associated with widespread degeneration 0.04
Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis 0.12
Genetic modifiers of somatic expansion and clinical phenotypes in Huntington’s disease highlight shared and tissue-specific effects 0.24
1 0.18
Population attributable fractions of a wide range of peripheral diseases for the burden of dementia 0.18
1 0.02
A transcriptomic microglia taxonomy across mouse and human pathologies 0.02
9 0.87
Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals 0.21
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial 0.03
The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial 0.05
Oral splicing modulator branaplam in Huntington’s disease: a phase 2 randomized controlled trial 0.06
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial 0.06
Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trial 0.05
AI-driven reclassification of multiple sclerosis progression 0.26
Shared and disease-specific pathways in frontotemporal dementia and Alzheimer’s and Parkinson’s diseases 0.11
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial 0.05
10 1.59
Magnetic resonance microscopy maps widespread effects of Alzheimer’s disease on brain structures and behavior in mice 0.05
A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions 0.02
The Alzheimer’s therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia 0.03
Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy 0.03
Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease 0.01
TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD 0.24
C9orf72 hexanucleotide repeat expansions impair microglial response in ALS 0.05
Hormonal milieu influences whole-brain structural dynamics across the menstrual cycle using dense sampling in multiple individuals 0.10
Evidence for trans-synaptic propagation of oligomeric tau in human progressive supranuclear palsy 1.00
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, genotype and sex 0.06
1 0.35
Distinct tau filament folds in human MAPT mutants P301L and P301Tc 0.35
1 0.58
The brain neurovascular epigenome and its association with dementia 0.58
1 0.31
Ischemic stroke triggers brain-wide synaptic remodeling within four hours 0.31
4 3.04
Association between gabapentinoid treatment, concurrent use with opioid or benzodiazepine and the risk of drug poisoning: A self-controlled case series study 0.82
Associations between epileptic seizures in pregnancy and adverse pregnancy outcomes: A systematic review and meta-analysis 0.96
Associations between falls and other serious adverse events and antihypertensive medication in individuals with dementia: An observational cohort study 0.81
Re-evaluating malarial retinopathy to improve its diagnostic accuracy in paediatric cerebral malaria: A retrospective study 0.44
5 2.72
Reversibility and β-sheet formation are decoupled in tau condensate aging 0.71
A hybrid compass mechanism combining radical pairs and magnetite crystals 1.00
Preservation of anticorrelated brain networks predicts recovery after traumatic brain injury 0.20
Dysregulated proteostasis in p.A53T-α-Synuclein astrocytes aggravates Lewy-like neuropathology in a Parkinson’s disease iPSC model 0.04
Analgesia through FKBP51 inhibition at disease onset confers lasting relief from sensory and emotional chronic pain symptoms 0.77
1 0.97
Diagnostic Value of Swallow Tail Sign at Brain MRI in Patients with Clinically Uncertain Parkinsonian Syndrome. 0.97
3 1.09
A global screen for magnetically induced neuronal activity in the pigeon brain 0.04
Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration 0.05
Dysfunction in primate dorsolateral prefrontal area 46 affects motivation and anxiety 1.00
9 4.18
Regulation of autism-related self-injurious behavior by electrical stimulation of corticostriatal circuits in mice and humans 0.02
Selective vulnerability of cerebral vasculature to NOTCH3 variants in small vessel disease and rescue by phosphodiesterase-5 inhibitor 0.79
Structural basis for domain coupling in heteromeric glycine receptors revealed by an atypical allosteric agonist 0.50
GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis 0.90
The chloride intracellular channel 1 (CLIC1) is essential for microglial morphodynamics and neuroinflammation 0.02
Differential modulation of movement speed with state-dependent deep brain stimulation in Parkinson’s disease 0.05
Dorsal raphe nucleus controls motivation-state transitions in monkeys 1.00
Reduced DJ-1-F1Fo ATP synthase association correlates with midbrain dopaminergic neuron vulnerability in idiopathic Parkinson’s disease 0.86
Proteomic signatures of corona and herpes viral antibodies identify IGDCC4 as a mediator of neurodegeneration 0.03
4 1.18
Selective targeting of mutant huntingtin intron 1 improves rescue provided by antisense oligonucleotides in Huntington’s disease mice 0.50
Lowering the HTT1a transcript as an effective therapy for Huntington’s disease in a knockin mouse model 0.62
Levetiracetam prevents Aβ production through SV2a-dependent modulation of APP processing in Alzheimer’s disease models 0.03
SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis 0.03
1 0.09
Accelerated continuous theta burst stimulation targeting left primary motor cortex for children with autism spectrum disorder: multicentre randomised sham controlled trial 0.09
4 1.70
Ubiquilin-2 liquid droplets catalyze α-synuclein fibril formation. 0.05
Direct interaction between TDP-43 and Tau promotes their co-condensation, while suppressing Tau fibril formation and seeding 0.05
Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2 0.75
Amyloid-β disrupts APP-regulated protein aggregation and dissociation from recycling endosomal membranes. 0.86
6 1.58
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials 0.03
Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial 0.04
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial 1.00
Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study 0.06
Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial 0.14
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial 0.32
6 2.16
Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial 1.00
Association between the Edinburgh CT and genetic diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage and recurrent intracerebral haemorrhage: an individual patient data meta-analysis 0.27
Sleep EEG and respiratory biomarkers of sudden unexpected death in epilepsy (SUDEP): a case–control study 0.05
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial 0.02
Effects of blood pressure lowering in relation to time in acute intracerebral haemorrhage: a pooled analysis of the four INTERACT trials 0.04
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study 0.77
1 0.49
The distinctive psychopathology of NMDAR-antibody encephalitis compared with primary psychoses: an international, multicentre, retrospective phenotypic analysis 0.49
5 0.39
Asundexian for Secondary Stroke Prevention 0.02
Zorevunersen in Children and Adolescents with Dravet Syndrome 0.18
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion 0.01
Risdiplam in Presymptomatic Spinal Muscular Atrophy 0.17
Intravenous Tenecteplase before Thrombectomy in Stroke 0.02

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.